Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel L Rutishauser

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Science Advances|July 31, 2021
SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assayMichael J Peluso, Saki Takahashi, Jill Hakim, et al.
Medrxiv : the Preprint Server for Health Sciences|March 24, 2021
Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19Michael J Peluso, J Daniel Kelly, Scott Lu, et al.
Open Forum Infectious Diseases|February 2, 2022
Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for MeasurementMichael J Peluso, J Daniel Kelly, Scott Lu, et al.
The Lancet. Microbe|May 19, 2025
Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern AfricaChama Chanda, Freddie Kibengo, Michael Mutua, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Science Advances|July 31, 2021
SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assayMichael J Peluso, Saki Takahashi, Jill Hakim, et al.
Medrxiv : the Preprint Server for Health Sciences|March 24, 2021
Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19Michael J Peluso, J Daniel Kelly, Scott Lu, et al.
Open Forum Infectious Diseases|February 2, 2022
Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for MeasurementMichael J Peluso, J Daniel Kelly, Scott Lu, et al.
The Lancet. Microbe|May 19, 2025
Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern AfricaChama Chanda, Freddie Kibengo, Michael Mutua, et al.
Pageof 5